Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 4/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20711945 | 0.87 | MEN1 (0.35) | CACNA1BNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20712024 | 0.85 | CACNA1B (0.37) | KLK7KLK5CACNA1BTACR1SCN9A | |
| SCHEMBL20712109 | 0.84 | TACR1 (0.36) | KLK7CACNA1BTACR1SCN9ASCN10A | |
| SCHEMBL20712022 | 0.84 | CASP3 (0.32) | TACR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20711941 | 0.83 | KLK7 (0.40) | KLK7KLK5P2RY2 | |
| SCHEMBL7736866 | 0.83 | CASP3 (0.32) | TACR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29867943 | 0.83 | CASP3 (0.32) | TACR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20711953 | 0.83 | KLK7 (0.42) | KLK7KLK5 | |
| SCHEMBL20712077 | 0.81 | KLK7 (0.37) | KLK7KLK5CACNA1BTACR1CTSK | |
| SCHEMBL23541501 | 0.80 | KCNA5 (0.41) | SCN9ASCN10ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190038621-A1 | POSACONAZOLE DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190038621-A1 | POSACONAZOLE DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | CYP3A43, ERG28, SORD | KLK7 2124/4885KLK5 2883/4885CACNA1B 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.